{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "JPY", "marketState": "CLOSED", "exchangeTimezoneShortName": "JST", "gmtOffSetMilliseconds": 32400000, "esgPopulated": false, "regularMarketChangePercent": 0.7843138, "regularMarketPrice": 2827.0, "exchange": "JPX", "shortName": "SOSEI GROUP CORP", "longName": "Sosei Group Corporation", "messageBoardId": "finmb_1266465", "exchangeTimezoneName": "Asia/Tokyo", "market": "jp_market", "regularMarketTime": 1683872101, "regularMarketDayHigh": 2846.0, "regularMarketDayRange": "2768.0 - 2846.0", "regularMarketDayLow": 2768.0, "regularMarketVolume": 1062800, "regularMarketPreviousClose": 2805.0, "bid": 2826.0, "ask": 2830.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Tokyo", "financialCurrency": "JPY", "regularMarketOpen": 2790.0, "averageDailyVolume3Month": 1337815, "averageDailyVolume10Day": 1951200, "fiftyTwoWeekLowChange": 1836.0, "fiftyTwoWeekLowChangePercent": 1.852674, "fiftyTwoWeekRange": "991.0 - 2897.0", "fiftyTwoWeekHighChange": -70.0, "fiftyTwoWeekHighChangePercent": -0.024162928, "fiftyTwoWeekLow": 991.0, "fiftyTwoWeekHigh": 2897.0, "earningsTimestamp": 1683873000, "earningsTimestampStart": 1691476200, "earningsTimestampEnd": 1691994600, "trailingAnnualDividendRate": 0.0, "trailingPE": 628.2222, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 4.5, "epsForward": 2.33, "sharesOutstanding": 81923000, "bookValue": 707.201, "fiftyDayAverage": 2476.36, "fiftyDayAverageChange": 350.6399, "fiftyDayAverageChangePercent": 0.14159487, "twoHundredDayAverage": 2091.1, "twoHundredDayAverageChange": 735.8999, "twoHundredDayAverageChangePercent": 0.35191998, "marketCap": 233489842176, "forwardPE": 1213.3048, "priceToBook": 3.9974492, "sourceInterval": 15, "exchangeDataDelayedBy": 20, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1091059200000, "priceHint": 2, "regularMarketChange": 22.0, "symbol": "4565.T"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "PMO Hanzomon", "address2": "11th Floor 2-1 Kojimachi Chiyoda-ku", "city": "Tokyo", "zip": "102-0083", "country": "Japan", "phone": "81 3 5210 3290", "website": "https://soseiheptares.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.", "fullTimeEmployees": 202, "companyOfficers": [{"maxAge": 1, "name": "Mr. Shinichi  Tamura", "age": 73, "title": "Founder & Chairman", "yearBorn": 1949, "fiscalYear": 2021, "totalPay": {"raw": 328000000, "fmt": "328M", "longFmt": "328,000,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chris  Cargill", "age": 38, "title": "Representative Exec. Officer, Pres, CEO & Director", "yearBorn": 1984, "fiscalYear": 2021, "totalPay": {"raw": 231000000, "fmt": "231M", "longFmt": "231,000,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Hironoshin  Nomura", "title": "Sr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kieran  Johnson F.C.A.", "title": "Exec. Officer, VP & Chief Accounting Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Miles  Congreve", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kazuhiko  Yoshizumi", "age": 68, "title": "Exec. Officer, VP & Chief Compliance Officer", "yearBorn": 1954, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Shinichiro  Nishishita", "title": "VP of Investor Relations & Head of Regulatory Disclosures", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Stacey  Southall", "title": "Associate Director & Head of Biophysics", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Candelle  Chong", "title": "Exec. Officer, Exec. VP & Chief of Staff", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Matt  Barnes", "title": "Head of Drug Discovery, Exec. Officer, VP, Pres of Heptares Therapeutics Ltd. & Head of UK R&D", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}